Hemolysis, Icterus, and Lipemia Interference Limits for Serum β-hydroxybutyrate Testing
The Journal of Applied Laboratory Medicine · 2026
DOI: 10.1093/jalm/jfag001 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2026. Verfasst von Mark A Cervinski und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, The Geisel School of Medicine at Dartmouth, One Medical Center Dr., Lebanon, NH, United States. Hauptthemen laut MEDLINE: Hemolysis, Hyperlipidemias, 3-Hydroxybutyric Acid, Jaundice. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Measurement of β-hydroxybutyrate (BOHB) is a valuable tool for the assessment of metabolic acidoses. In this study we evaluated hemolysis, icterus, and lipemia interference thresholds for a commonly used BOHB assay, the Stanbio β-Hydroxybutyrate LiquiColor reagent, on 3 different Roche cobas analyzers.
Methods
Remnant patient samples were combined to generate pools with target BOHB concentrations of approximately 0.20, 3.00, and 7.00 mmol/L into which increasing amounts of hemolysate, bilirubin, or Intralipid® were added. Samples were measured in triplicate for both interferences and BOHB concentration on Roche cobas c502, c501, and c311 analyzers.
Results
We determined that the Stanbio β-Hydroxybutyrate LiquiColor reagent will tolerate hemolysis to a hemolysis index of 400 (approximately 400 mg/dL hemoglobin) for BOHB concentrations ≤1.00 mmol/L, or 1010 for BOHB concentrations of >1.00 mmol/L. For icterus, the assay was unaffected by bilirubin to an icterus index of 25 [approximately 25 mg/dL bilirubin (427 μmol/L)] for all concentrations tested. Using the most conservative data from our study, the lipemia index limit was set at 800.
Conclusions
Our studies across 3 laboratories running 3 different cobas modules allowed our health system to better define permissible limits of sample quality and these updated values will reduce the number of unnecessary cancelations as compared to the limits defined by the manufacturer. Our data also demonstrated heterogeneity of interference between analyzer models, which is an important consideration for those seeking to adopt the limits determined on analyzers other than those in their own laboratories.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, The Geisel School of Medicine at Dartmouth, One Medical Center Dr., Lebanon, NH, United States.
- Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, One Medical Center Dr., Lebanon, NH, United States.
ORCID-Profile: Mark A Cervinski
Zitieren
APA
Cervinski, M. A., Smith, M. J., Forgues, G., & Brunelle, L. A. (2026). Hemolysis, Icterus, and Lipemia Interference Limits for Serum β-hydroxybutyrate Testing. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfag001
Vancouver
Cervinski MA, Smith MJ, Forgues G, Brunelle LA. Hemolysis, Icterus, and Lipemia Interference Limits for Serum β-hydroxybutyrate Testing. The Journal of Applied Laboratory Medicine. 2026. doi:10.1093/jalm/jfag001
BibTeX
@article{Cervinski2026,
author = {Cervinski, Mark A and Smith, Macey J and Forgues, Gracie and Brunelle, Lynn A},
title = {Hemolysis, Icterus, and Lipemia Interference Limits for Serum β-hydroxybutyrate Testing},
journal = {The Journal of Applied Laboratory Medicine},
year = {2026},
doi = {10.1093/jalm/jfag001}
}
EUVIMED